• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Increased Odds of Metabolic Dysfunction-Associated Steatotic Liver Disease Are Linked to Reduced n-6, but Not n-3 Polyunsaturated Fatty Acids in Plasma.血浆中 n-6 多不饱和脂肪酸减少与代谢功能障碍相关的脂肪性肝病的几率增加有关,但 n-3 多不饱和脂肪酸无关。
Biomolecules. 2024 Jul 25;14(8):902. doi: 10.3390/biom14080902.
2
Low unesterified:esterified eicosapentaenoic acid (EPA) plasma concentration ratio is associated with bipolar disorder episodes, and omega-3 plasma concentrations are altered by treatment.低游离型:酯化二十碳五烯酸(EPA)血浆浓度比值与双相情感障碍发作有关,且ω-3血浆浓度会因治疗而改变。
Bipolar Disord. 2015 Nov;17(7):729-42. doi: 10.1111/bdi.12337. Epub 2015 Oct 1.
3
Plasma phospholipid n-3 and n-6 polyunsaturated fatty acids in relation to cardiometabolic markers and gestational diabetes: A longitudinal study within the prospective NICHD Fetal Growth Studies.血浆磷脂 n-3 和 n-6 多不饱和脂肪酸与心脏代谢标志物和妊娠糖尿病的关系:前瞻性 NICHD 胎儿生长研究中的纵向研究。
PLoS Med. 2019 Sep 13;16(9):e1002910. doi: 10.1371/journal.pmed.1002910. eCollection 2019 Sep.
4
Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease.在患有脂肪性肝病的个体中,肝脂肪变性而非2型糖尿病、体重指数或肝纤维化与高胰高血糖素血症相关。
Am J Physiol Gastrointest Liver Physiol. 2024 Oct 1;327(4):G558-G570. doi: 10.1152/ajpgi.00147.2024. Epub 2024 Aug 6.
5
Association of Plasma Phospholipid n-3 and n-6 Polyunsaturated Fatty Acids with Type 2 Diabetes: The EPIC-InterAct Case-Cohort Study.血浆磷脂n-3和n-6多不饱和脂肪酸与2型糖尿病的关联:欧洲癌症与营养前瞻性调查(EPIC)-InterAct病例队列研究
PLoS Med. 2016 Jul 19;13(7):e1002094. doi: 10.1371/journal.pmed.1002094. eCollection 2016 Jul.
6
Hormonal and metabolic effects of polyunsaturated fatty acids in young women with polycystic ovary syndrome: results from a cross-sectional analysis and a randomized, placebo-controlled, crossover trial.多囊卵巢综合征年轻女性多不饱和脂肪酸的激素和代谢作用:来自横断面分析和随机、安慰剂对照、交叉试验的结果。
Am J Clin Nutr. 2011 Mar;93(3):652-62. doi: 10.3945/ajcn.110.005538. Epub 2011 Jan 26.
7
Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD.ω-3 脂肪酸补充剂的脂类种类对 MASLD 患者肝脏脂肪堆积的影响。
Physiol Res. 2024 Aug 31;73(Suppl 1):S295-S320. doi: 10.33549/physiolres.935396. Epub 2024 Jul 17.
8
Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity.脂质组学分析揭示了肥胖患者 MASLD 分期相关的肝脂肪 FA 谱改变。
J Clin Endocrinol Metab. 2024 Jun 17;109(7):1781-1792. doi: 10.1210/clinem/dgae028.
9
Nonlinear relationships of circulating polyunsaturated fatty acids with the complications of liver cirrhosis: A prospective, longitudinal cohort study.循环多不饱和脂肪酸与肝硬化并发症的非线性关系:一项前瞻性、纵向队列研究。
Clin Nutr. 2024 Sep;43(9):2083-2091. doi: 10.1016/j.clnu.2024.07.027. Epub 2024 Jul 31.
10
Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic.日本代谢相关脂肪性肝病:2019 年冠状病毒病大流行前 10 年的流行趋势及临床背景。
Medicina (Kaunas). 2024 Aug 16;60(8):1330. doi: 10.3390/medicina60081330.

引用本文的文献

1
Dietary Strategies in the Prevention of MASLD: A Comprehensive Review of Dietary Patterns Against Fatty Liver.预防代谢相关脂肪性肝病的饮食策略:针对脂肪肝的饮食模式综合综述
Metabolites. 2025 Aug 4;15(8):528. doi: 10.3390/metabo15080528.
2
Metabolic Dysfunction-Associated Steatotic Liver Disease Is Characterized by Enhanced Endogenous Cholesterol Synthesis and Impaired Synthesis/Absorption Balance.代谢功能障碍相关脂肪性肝病的特征是内源性胆固醇合成增强以及合成/吸收平衡受损。
Int J Mol Sci. 2025 Aug 1;26(15):7462. doi: 10.3390/ijms26157462.

本文引用的文献

1
Updated mechanisms of MASLD pathogenesis.MASLD 发病机制的更新机制。
Lipids Health Dis. 2024 Apr 22;23(1):117. doi: 10.1186/s12944-024-02108-x.
2
Current status and future trends of the global burden of MASLD.全球 MASLD 负担的现状和未来趋势。
Trends Endocrinol Metab. 2024 Aug;35(8):697-707. doi: 10.1016/j.tem.2024.02.007. Epub 2024 Feb 29.
3
Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD).代谢相关脂肪性肝病(MASLD)中的脂质代谢
Metabolites. 2023 Dec 23;14(1):12. doi: 10.3390/metabo14010012.
4
MASLD treatment-a shift in the paradigm is imminent.非酒精性脂肪性肝病治疗——范式转变即将来临。
Front Med (Lausanne). 2023 Dec 11;10:1316284. doi: 10.3389/fmed.2023.1316284. eCollection 2023.
5
A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF-β signaling in hepatic stellate cells.亚油酸的一种肠道微生物代谢产物通过抑制肝星状细胞中的 TGF-β 信号通路改善肝纤维化。
Sci Rep. 2023 Nov 3;13(1):18983. doi: 10.1038/s41598-023-46404-5.
6
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.代谢功能障碍相关脂肪性肝病(MASLD):最新综述
J Obes Metab Syndr. 2023 Sep 30;32(3):197-213. doi: 10.7570/jomes23052. Epub 2023 Sep 13.
7
Conjugated linoleic acid (CLA) as a functional food: Is it beneficial or not?共轭亚油酸(CLA)作为一种功能性食品:它是否有益?
Food Res Int. 2023 Oct;172:113158. doi: 10.1016/j.foodres.2023.113158. Epub 2023 Jun 25.
8
Obesity and Dyslipidemia: A Review of Current Evidence.肥胖与血脂异常:当前证据综述。
Curr Obes Rep. 2023 Sep;12(3):207-222. doi: 10.1007/s13679-023-00518-z. Epub 2023 Jul 6.
9
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识:新的非酒精性脂肪性肝病命名。
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
10
Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).过氧化物酶体增殖物激活受体(PPARs)在非酒精性脂肪性肝病(NAFLD)发病机制中的作用。
Pharmacol Res. 2023 Jun;192:106786. doi: 10.1016/j.phrs.2023.106786. Epub 2023 May 3.

血浆中 n-6 多不饱和脂肪酸减少与代谢功能障碍相关的脂肪性肝病的几率增加有关,但 n-3 多不饱和脂肪酸无关。

Increased Odds of Metabolic Dysfunction-Associated Steatotic Liver Disease Are Linked to Reduced n-6, but Not n-3 Polyunsaturated Fatty Acids in Plasma.

机构信息

Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia.

Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.

出版信息

Biomolecules. 2024 Jul 25;14(8):902. doi: 10.3390/biom14080902.

DOI:10.3390/biom14080902
PMID:39199290
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11353166/
Abstract

The increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) underscores the need for better understanding of its complex pathogenesis. Lipid accumulation in hepatocytes is among principal mechanisms contributing to MASLD development. While routine lipid parameters are well studied, the profile of circulating fatty acids in MASLD patients remains less explored. This study aimed to assess relative proportions of individual fatty acids in plasma of MASLD patients and to explore their associations with other biochemical markers of MASLD. Ninety-one patients and 48 healthy individuals were enrolled. The relative proportions of fatty acids in plasma were determined using gas chromatography with FID detection. Proportions of total n-6 polyunsaturated fatty acids (PUFAs) and linoleic acid (LA) in plasma were lower in MASLD patients ( = 0.001 and = 0.004, respectively), with no differences observed in n-3 PUFAs. Total plasma n-6 PUFAs correlated negatively with body mass index, hepatic steatosis indices, triglyceride concentration and coronary risk index. Decreased prevalence of n-6 PUFAs in plasma was independently associated with higher odds of MASLD (OR = 0.769; CI: 0.611-0.968; = 0.025). Our findings indicate an altered circulatory fatty acid distribution in MASLD, characterized by a reduced amount of n-6 PUFAs, particularly LA, which may have significant implications for the prevention and treatment of MASLD.

摘要

代谢功能障碍相关脂肪性肝病(MASLD)的患病率不断上升,这凸显了人们对其复杂发病机制的深入理解的必要性。肝细胞内脂质积累是导致 MASLD 发生的主要机制之一。虽然常规脂质参数已得到充分研究,但 MASLD 患者循环脂肪酸的特征仍未得到充分探索。本研究旨在评估 MASLD 患者血浆中单个脂肪酸的相对比例,并探讨其与 MASLD 其他生化标志物的相关性。共纳入 91 例 MASLD 患者和 48 例健康对照者。采用气相色谱法(带 FID 检测器)测定血浆中脂肪酸的相对比例。MASLD 患者血浆中总 n-6 多不饱和脂肪酸(PUFA)和亚油酸(LA)的比例较低(分别为 = 0.001 和 = 0.004),而 n-3 PUFA 则无差异。总血浆 n-6 PUFA 与体重指数、肝脂肪变性指数、甘油三酯浓度和冠状动脉风险指数呈负相关。血浆 n-6 PUFA 减少与 MASLD 的患病风险增加独立相关(OR = 0.769;95%CI:0.611-0.968; = 0.025)。我们的研究结果表明,MASLD 患者存在循环脂肪酸分布异常,表现为 n-6 PUFA,特别是 LA 的含量减少,这可能对 MASLD 的预防和治疗具有重要意义。